Dipeptide Ingredients TRIZ Cases

Replacing solid phase synthesis with liquid phase enzymatic catalysis in nonpolar solvents prevents gelling and eliminates expensive condensing agents.

Measuring immunoglobulin expression levels guides proteasome inhibitor treatment selection.

Nitrile warhead inhibitors reversibly bond to conserved cysteine residues, enabling broad-spectrum activity against diverse coronavirus strains.

Activatable cell penetrating peptides deliver MMAE into tumor cells via endocytosis.

Polyethylene glycol conjugates increase protease inhibitor potency and stability, eliminating the need for CYP3A4 inhibitors to improve patient compliance.

Synergistic calcium flux agonist and PRR ligand composition accelerates wound closure in sterile injuries while reducing infection risk.

Low dose SSAO inhibitor saturates plasma enzyme to reduce hepatic inflammation while improving patient compliance.

Allosteric ligand B1 reduces circulating tumor cell concentration and macrophage density to prevent cancer metastasis.

Herbal preparations from carnivorous plants increase fibroblast growth factors and decrease fibrinogen levels to promote tissue repair.

Methanotrophic microorganisms metabolize methane to synthesize polyhydroxyalkanoate polymers with controlled functional properties.

Peptidic compounds inhibit viral proteases, addressing the gap between in vitro efficacy and human patient results.

Crosslinked small peptides block multidrug resistance-associated protein transporters to prevent chemotherapeutic agent efflux.

A proteasome inhibitor combined with an RGD cyclic peptide targets integrins on cancer cells, reducing toxicity while enhancing therapeutic efficacy.

A non-immunosuppressive cyclosporin A derivative reduces muscle pathology and normalizes mitochondrial sensitivity to calcium overload.

Chromone derivatives inhibit the BCRP transporter, blocking efflux pumps that cause multidrug resistance and restoring chemotherapy efficacy.

Oral CTSC inhibitors reduce tumor volume and circulating NETs, addressing ineffective lung metastasis treatments.

Encapsulating bortezomib in boronic acid ester complexes within liposomes reduces peripheral neuropathy and myelosuppression while improving antitumor activity.

Boronic acid inhibitors selectively target immunoproteasomes to reduce side effects on normal tissues while maintaining therapeutic reliability.

Formula I compounds inhibit mutant IDH1 alpha hydroxyl neoactivity, reducing toxic 2HG levels in cancers with IDH1 or IDH2 mutations.

A dipeptide and curcumin formulation reduces muscle cramp frequency without adverse effects.

A mitochondria-targeting conjugate self-assembles into fibrils within carcinoma cells to induce apoptosis.

Mitochondria-penetrating peptides transport drugs to mitochondria, resolving cytosolic toxicity and enhancing bioavailability.

Alpha7beta1 integrin modulatory agents increase receptor expression to enhance muscle regeneration and repair processes.

Specific peptides Gly-Pro and Glu-Hyp-Gly promote type 17 collagen synthesis to suppress hair loss and depigmentation.

Crystallizing perindopril erbumine in wet aliphatic ester reduces diketopiperazine impurities below 0.20% w/w, simplifying purification.